Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Laser zaps away reading glasses for Post-Cataract patients?

NCT ID NCT07384182

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a low-energy femtosecond laser (the Perfector device) to treat presbyopia in 19 people who already had monofocal lens implants from cataract surgery. The goal was to improve near and intermediate vision without harming distance vision. Participants were measured on how well they could read letters at 40 cm and 66 cm, and at 4 meters. The study is complete, but because it was small and had no comparison group, the results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
femtosecond laser device (Perfector)
What this could lead to
If it works, this could offer a way to improve reading vision without glasses for people who already have standard lens implants after cataract surgery.
What could go wrong
This was a very small study (19 people) with no control group, so results may not apply widely. The procedure involves attaching a device to the eye with suction, which carries some risk of discomfort or minor injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Oct 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ability to understand study requirements, follow study instructions and to return for required study follow-up visits as confirmed by provision of written informed consent; 2. Subject has undergone cataract surgery and has had a monofocal lens implanted in both eyes; 3. Subject has no significant residual visual issues which the Investigator believes would make the patient ill suited for the Treatment.; and 4. Both eyes have CDVA vision of 20/25 or better at 4m. Exclusion Criteria: 1. Subjects not able to complete the informed consent form; 2. Clinically significant corneal abnormalities including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), inflammation, keratitis, keratoconjunctivitis, keratouveitis, keratopathy, keratectasia or edema per the Investigator's expert medical opinion; 3. Previous corneal surgery; 4. Previous refractive surgery or proposed refractive surgery procedures throughout the entire duration of the subjects' participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions); 5. History of or current retinal conditions or predisposition to retinal conditions including retinal detachment, diabetic retinopathy, age related macular degeneration which are assessed to by investigator to confound outcomes; 6. Amblyopia; 7. History of or current anterior or posterior segment inflammation of any etiology, or any disease-producing an inflammatory reaction in the eye (e.g., iritis or uveitis); 8. Optic nerve atrophy; 9. Iris neovascularization; 10. Subjects with diagnosed degenerative eye disorders (e.g., macular degeneration or other retinal disorders); 11. Uncontrolled glaucoma; 12. Any subject currently participating in another investigational drug or device studies; and 13. Any subject disqualified by the Principal Investigator or Medical Monitor for any ocular issue.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gemini Eye Clinic

    Zlín, Czech Republic, 760 01, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.